Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track PBYI with free AI briefings, catalyst countdowns, and dilution alerts.

PBYI · PUMA BIOTECHNOLOGY, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$93.9M Cash on Hand

CF+ Cash Runway

Follow PBYI by email Get an email when PBYI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PBYI, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Oct 2027 · Phase 2 · Recruiting · A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Registry primary completion date, not a results date
Dec 2027 · Phase 2 · Recruiting · A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, H
Registry primary completion date, not a results date
Mar 2028 · Phase 2 · Recruiting · A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Neratinib (HKI-272) FDA approved Jul 2017 · Nerlynx	HER2+ Metastatic Breast Cancer (MBC)	Phase 3 · NCT01808573	Completed
Fluorouracil	GastroEsophageal Cancer	Phase 2 · NCT06109467	Active not recruiting
Loperamide	Early-stage Breast Cancer	Phase 2 · NCT05252988	Active not recruiting
Cytotoxic Agent-LAT1 Substrate QBS10072S	Glioblastoma	Phase 2 · NCT02977780	Recruiting
Trastuzumab Emtansine	Breast Cancer	Phase 1/2 · NCT02236000	Completed
Endocrine therapy	Hormone Receptor Positive HER-2 Negative Breast Ca	Phase 2 · NCT06369285	Recruiting
Alisertib	Hormone Receptor Positive HER-2 Negative Breast Ca	Phase 2 · NCT06369285	Recruiting
DNA-PK/TOR Kinase Inhibitor CC-115	Glioblastoma	Phase 2 · NCT02977780	Recruiting
Colestipol	Early Stage HER2+ Breast Cancer	Phase 2 · NCT02400476	Completed
Doxorubicin	Breast Cancer	Phase 2 · NCT01008150	Completed
Diphenoxylate	HER2-positive Breast Cancer	Phase 2 · NCT03094052	Completed
Osimertinib	Lung Cancer Metastatic	Phase 1 · NCT04085315	Completed
Niraparib at RP2D	Advanced Solid Tumor	Phase 1 · NCT04502602	Active not recruiting
Neratinib Pill	Gastric Cancer	Phase 1 · NCT05274048	Recruiting
Neratinib at RP2D	Advanced Solid Tumor	Phase 1 · NCT04502602	Active not recruiting

Also used in these trials (approved or third-party drugs, not PBYI's own candidates): Lapatinib, Capecitabine, Pembrolizumab, Fulvestrant, Oxaliplatin, Paclitaxel, Letrozole, Temozolomide, Temsirolimus, Trastuzumab, Vinorelbine, Abemaciclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PBYI holds $93.9M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PBYI files for a raise →

Get the full PBYI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBYI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z